Seven of the nine patients enrolled in the phase 1b study received at least one dose of rilotumumab 15 mg/kg , only two of whom had three dose-limiting toxicities : palmar-plantar erythrodysesthesia , cerebral ischaemia , and deep-vein thrombosis .